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Abstract: The present study investigated the genetic contribution to alcohol dependence (AD) using
genome-wide association data from three German samples. These comprised patients with: (i) AD;
(ii) chronic alcoholic pancreatitis (ACP); and (iii) alcohol-related liver cirrhosis (ALC). Single marker,
gene-based, and pathway analyses were conducted. A significant association was detected for the
ADH1B locus in a gene-based approach (puncorrected = 1.2 × 10−6; pcorrected = 0.020). This was driven
by the AD subsample. No association with ADH1B was found in the combined ACP + ALC sample.
On first inspection, this seems surprising, since ADH1B is a robustly replicated risk gene for AD and
may therefore be expected to be associated also with subgroups of AD patients. The negative finding
in the ACP + ALC sample, however, may reflect genetic stratification as well as random fluctuation of
allele frequencies in the cases and controls, demonstrating the importance of large samples in which
the phenotype is well assessed.
Keywords: alcohol dependence; chronic alcoholic pancreatitis; alcoholic liver cirrhosis; genome-wide
association study; alcohol dehydrogenase; ADH1B; ADH1C
1. Introduction
Genetic influences play a major role in the development of alcohol use disorders as formal genetic
studies in twins and epidemiological samples have shown [1–3]. Candidate studies and genome-wide
association studies (GWAS) have identified numerous candidate genes for alcohol dependence (AD)
and alcohol consumption (AC).
In candidate gene studies, the most consistently reported associations for both traits have been
obtained for the genes alcohol dehydrogenase 1B (ADH1B; chr4q23) [4], alcohol dehydrogenase 1C
(ADH1C; chr4q23) [5], and aldehyde dehydrogenase 2 (ALDH2; chr12q24) [6].
The advantage of GWAS studies which screen the entire genome with millions of variants is that
they facilitate gene identification in novel biological contexts. Indeed, recent successes have been
achieved for complex traits with low heritability, such as depression [7] in large samples comprising
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more than one hundred thousand individuals. Previous GWAS of AD have been conducted in
samples with a lower number of individuals [8–10]. However, they have also most consistently
identified variants in the ADH gene cluster. The up-to-now largest GWAS of AC which contained
more than one hundred thousand individuals from the UK Biobank, and identified ten loci reaching
genome-wide significance, also showed the best finding in the ADH1B/ADH1C region (rs145452708,
p = 8.93 × 10−29) [11]. Additionally, earlier GWAS of AC identified rs1229984 and other variants at the
chr4q22/q23 region in/near the ADH gene cluster [12–14].
A promising approach to mitigating the burden of multiple testing, which limits the single-marker
approach, is to analyze the aggregated contribution of variants in single genes and in functionally
related gene groups (e.g., biological pathways), under the assumption that these contain a large number
of variants with a disruptive influence on gene/pathway function.
In the present study, multi-marker analyses were performed in order to detect new genes and
pathways for AD and/or to confirm prior reported genes and pathways. To increase sample size
in order to maximize statistical power, individuals with alcohol-related somatic disease were also
included. Gene-wide significance for the ADH1B gene was detected in the combined sample. However,
the findings demonstrated that very large sample sizes are warranted to overcome heterogeneity
and/or random genetic fluctuation.
2. Materials and Methods
2.1. Participants
The cohort comprised individuals from three previously reported German samples: (i) 1331 AD
patients and 1934 controls [9]; (ii) 1110 patients with chronic alcoholic pancreatitis (ACP) [15]; and
(iii) 400 patients with alcohol-related liver cirrhosis (ALC) [16]. A control sample (n = 1750) for the
ACP + ALC cases was drawn from the Heinz Nixdorf Recall (HNR) study [17].
The study was approved by the ethics committee II of Medical Faculty Mannheim of Heidelberg
University study number 2012-361N-MA, and was carried out in accordance with the Declaration of
Helsinki. All subjects provided written informed consent prior to inclusion.
Alcohol dependence (AD) case-control subsample: A detailed description of the sample is
provided elsewhere [9]. All patients were of self-reported German ancestry, and fulfilled Diagnostic
and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria for AD [18]. The patients
were recruited from consecutive admissions to psychiatric units at university hospitals participating in
the German Addiction Research Network [19]. These five study centers are located in the following
areas of central and southern Germany: Mannheim, Bonn/Essen/Düsseldorf/Homburg, Regensburg,
Munich, and Mainz. Controls were drawn from the following three population-based epidemiological
cohorts: (i) KORA-gen [20]; (ii) PopGen [21]; and (iii) HNR [17]. Further controls were drawn at
random from a Munich community sample screened using the Composite International Diagnostic
Interview. The AD case-control subsample is part of the Psychiatric Genomics Consortium (PGC) [22].
The GWAS data from the samples can be made available within the context of research collaborations.
Chronic alcoholic pancreatitis (ACP) patients: A diagnosis of ACP was assigned in patients
with a history of ≥2 years ingestion of ≥80 g alcohol/day (men), or ≥60 g/day (women). Most
patients exceeded these cut-offs for level and/or duration. The cohort included patients from a
number of European countries [15]. However, only German ACP patients were included in the present
analyses. These individuals were recruited in Berlin, Dresden, Erlangen, Heidelberg, Greifswald,
Leipzig, Magdeburg, Mannheim, and Munich.
Alcohol-related liver cirrhosis (ALC) patients: A detailed description of the criteria used
to define case status is provided in [16]. ALC patients presented with clinically-diagnosed, or
biopsy-confirmed, cirrhosis and a ≥10-year history of a past and/or present alcohol consumption level
of ≥80 g/day (men), or ≥60 g/day (women). In all cases, other causes of cirrhosis were excluded.
ALC cases were recruited from university hospital departments of hepatology and gastroenterology
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in: (i) Germany (Bonn, Regensburg, Dresden, Leipzig, Kiel, Frankfurt); (ii) Austria (Salzburg); and
(iii) Switzerland (Bern).
Controls for ACP and ALC patients: Controls were drawn from the HNR study [17].
2.2. Genotyping
AD case-control subsample: Patient samples were individually genotyped using the Illumina
HumanHap550, Human610Quad, or Human660w Quad BeadChips (Illumina, Inc., San Diego, CA,
USA). Controls were genotyped using the Illumina HumanHap550 Bead Chip.
ACP patient subsample, ALC patient subsample, and control sample for ACP and ALC patients:
The individuals were genotyped using the Illumina Omni Express BeadChip.
2.3. Quality Control
Quality control (QC) and single marker association testing were performed using PLINK
v1.9 [23]. Prior to QC, the genotype data of the three samples were merged. QC of the merged
data was performed in accordance with the protocol of the Schizophrenia Working Group of the
Psychiatric Genomics Consortium [24]. The analyses were restricted to autosomal single nucleotide
polymorphisms (SNPs) only. In the combined sample, genetic outliers were identified using principal
component analysis (PCA). Outlier status was defined as the presence of data points located more
than 6 standard deviations from the mean on any of the first 20 principal components. The respective
individuals were excluded from further analysis. After the removal of PCA outliers, the first and
second principal components showed a nominally significant association with AD, and were included
as covariates in all association analyses. As the present sample was comparatively small, a stringent
Hardy–Weinberg Equilibrium (HWE) test cutoff of p > 0.05 was applied to the controls of the combined
sample in order to optimize the quality of the genotyping clusters for the purposes of multimarker
analysis. A total of 6525 (out of 6894) individuals and 257,866 variants passed all filters. Of the
6525 individuals, 2841 were cases (1331 AD patients, 1110 ACP patients, 400 ALC patients), and 3684
were controls (1934 controls from the AD subsample, and 1750 controls for the combined ACP and
ALC patient sample). After linkage disequilibrium (LD)-based pruning (Variance Inflation Factor of
10), a total of 194,024 SNPs remained for the combined sample and subsample analyses.
2.4. Statistical Analysis
The single marker analysis was conducted using PLINK v1.9 [23]. This involved logistic regression,
an additive model of inheritance and correction for population stratification by including the first
two principal components as covariates. Gene-based and pathway-based analysis was conducted
using MAGMA v1.04 [25]. For the pathway analysis, output files from the gene-based analysis were
used as input. SNPs were assigned to a gene if the variant was located within the gene sequence or
within 20 kb of the transcript. If a variant was located within a region shared by more than one gene,
the variant was assigned to all of the respective genes. Version 5.1 of the Reactome database set was
retrieved from the Molecular Signatures Database [26]. The Reactome v5.1 set comprises 674 pathways.
For the post hoc analysis, genotypes for the ADH variant rs1789891 were counted using the “hardy”
option in PLINK. Deviation from HWE (exact test) was calculated using the DeFinetti program [27].
SNAP [28] was used to generate the regional association plot. The database dbSNP [29] was used to
retrieve the nucleotide triplet for the amino acid exchange.
3. Results
A single marker analysis in the combined sample generated no genome-wide significant findings
(Table S1). The top five variants were: (i) rs10392 (p = 8.336 × 10−7; Odds Ratio (OR) = 1.252), located
in PPP1R16B (protein phosphatase 1 regulatory subunit 16B), and near FAM83D (family with sequence
similarity 83 member D); (ii) rs454510 (3.334 × 10−6; OR = 1.206) near zinc finger protein 697 (ZNF697);
(iii) rs2028201 (4.928 × 10−6; OR = 1.183) in spermatogenesis associated serine rich 2 like (SPATS2L);
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(iv) intergenic variant rs926544 (p = 1.133 × 10−5; OR = 0.8113) and (v) rs1789891 (p = 1.315 × 10−5;
OR = 1.232) near alcohol dehydrogenase 1B (ADH1B) and near alcohol dehydrogenase 1C (ADH1C).
In the gene-based approach, only one finding achieved genome-wide significance. This was
the association with alcohol dehydrogenase 1B (ADH1B) (puncorrected = 1.2 × 10−6; pcorrected = 0.020;
Table 1). The Bonferroni corrected gene-based genome-wide significance threshold was 2.9 × 10−6
(0.05/16853 genes). In the combined genotype data, 16,853 genes were represented. Table 2 shows
the variants of the ADH1B locus that were included in the gene-based analysis. This association was
driven by the AD subsample (AD: puncorrected = 6.5 × 10−10; ACP + ALC: puncorrected = 0.69).
Table 1. Results of the gene-based analysis in the combined sample, and the respective p-values in the
subsamples. Genes with puncorrected < 1.0 × 10−4 are shown. If a variant was located within a region
shared by more than one gene, the variant was assigned to all of the respective genes.
Gene Position (hg18)
p-Value in the
Combined Sample
(2841 Cases, 3684
Controls)
p-Value in the ACP
+ ALC Subsample
(1510 Cases, 1750
Controls)
p-Value in the AD
Subsample (1331
Cases, 1934
Controls)
Alcohol Dehydrogenase 1B
(ADH1B)
chr4:
100426552-100481581 1.209 × 10
−6 0.68776 6.5258 × 10−10
Family with Sequence
Similarity 83 Member D
(FAM83D)
chr20:
36968369-37035117 4.2443 × 10
−6 0.0070016 0.34143
Alcohol Dehydrogenase 1C
(ADH1C)
chr4:
100456672-100512940 9.9601 × 10
−6 0.86648 8.5406 × 10−10
Zinc finger protein 697
(ZNF697)
chr1:
119943523-120011913 2.3488 × 10
−5 0.0011435 0.0087101
Ras Homolog Family Member
T2 (RHOT2) chr16: 638134-684172 3.006 × 10
−5 0.025274 0.00029276
Crystallin Zeta (CRYZ) chr1: 74923772-74991315 3.0976 × 10−5 0.051974 0.00084007
X-ray repair cross
complementing 5 (XRCC5)
chr2:
216662378-216799248 3.4649 × 10
−5 0.27561 2.7093 × 10−5
COX14 Cytochrome C
Oxidase Assembly Factor
(COX14)
chr12:
48772167-48820501 3.7703 × 10
−5 0.0017051 0.0044189
Rhomboid, Veinlet-Like 1
(RHBDL1) chr16: 646076-688268 4.5926 × 10
−5 0.026591 0.00033002
LOC440330 (LOC440330) chr16: 648519-689772 4.5926 × 10−5 0.026591 0.00033002
STIP1 homology and U-box
containing protein 1 (STUB1) chr16: 650116-692769 4.5926 × 10
−5 0.026591 0.00033002
Jumonji domain containing 8
(JMJD8) chr16: 651668-694440 4.62 × 10
−5 0.026732 0.00035589
WD Repeat Domain 24
(WDR24) chr16: 654703-700401 4.62 × 10
−5 0.026732 0.00035589
F-Box and Leucine-Rich
Repeat Protein 16 (FBXL16) chr16: 662503-715809 4.62 × 10
−5 0.026732 0.00035589
Olfactomedin Like 2A
(OLFML2A)
chr9:
126559258-126636982 4.8774 × 10
−5 0.00044653 0.015794
AD: Alcohol dependence; ACP: Chronic alcoholic pancreatitis; ALC: Alcohol-related liver cirrhosis.
The ADH variant which made the strongest contribution to the gene-wide significance of ADH1B
was rs1789891, which is located within ±20 kb of ADH1B and ADH1C and contributes to the
gene-based p-values of both genes (Figure S1). The rs1789891 association was driven by the AD
subsample (combined sample: p = 1.315 × 10−5, ORA-allele = 1.232; ACP + ALC subsample: p = 0.6392,
ORA-allele = 1.033; AD subsample: p = 1.642 × 10−8, ORA-allele = 1.469) (Table S1). The rs1789891 “risk”
allele was A and the “protective” allele was C.
In the control population of the combined cohort, the rs1789891 allele frequency was 0.154 for
the A-allele. The A-allele frequency of the controls was 0.141 for the AD subsample and 0.169 for the
ACP + ALC subsample (Table 3), the latter being similar to that reported in the 1000 Genomes Phase 3
data (A-allele: 0.167; CEU subpopulation) [30].
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Table 2. Variants used as input for the gene-based analysis of ADH1B (±20 kb;
chr4:100426552-100481581; hg18). Single marker association puncorrected-values shown, as calculated
using logistic regression in PLINK.
SNP (Genotypes)
p-Value in the Combined
Sample (2841 Cases, 3684
Controls); [OR]; Genotype
Counts : All (MAF), Affected
(MAF), Unaffected (MAF)
p-Value in the ACP + ALC
Subsample (1510 Cases, 1750
Controls); [OR]; Genotype
Counts: All (MAF), Affected
(MAF), Unaffected (MAF)
p-Value in the AD Subsample
(1331 Cases, 1934 Controls);
[OR]; Genotype Counts: All
(MAF), Affected (MAF),
Unaffected (MAF)
rs1159918 (TT/TG/GG)
0.6477 0.6256 0.271
[1.018] [0.9732] [1.061]
731/2941/2846 (0.3378) 360/1486/1407 (0.3391) 371/1455/1439 (0.3364)
324/1285/1227 (0.3408) 169/679/657 (0.3379) 155/606/570 (0.3441)
407/1656/1619 (0.3354) 191/807/750 (0.3401) 216/849/869 (0.3312)
rs1229982 (TT/TG/GG)
0.2306 0.6865 0.1655
[0.947] [0.9738] [0.9153]
262/2034/4229 (0.196) 127/1015/2118 (0.1946) 135/1019/2111 (0.1974)
104/884/1853 (0.1922) 52/485/973 (0.195) 52/399/880 (0.189)
158/1150/2376 (0.199) 75/530/1145 (0.1943) 83/620/1231 (0.2032)
rs9307239 (TT/TC/CC)
0.5449 0.5695 0.6132
[0.9781] [0.9707] [0.974]
1084/3105/2334 (0.4042) 581/1556/1121 (0.4171) 503/1549/1213 (0.3913)
485/1307/1047 (0.401) 278/688/542 (0.4125) 207/619/505 (0.3881)
599/1798/1287 (0.4066) 303/868/579 (0.4211) 296/930/708 (0.3935)
rs1789891 (AA/AC/CC)
1.315 × 10−5 0.6392 1.642 × 10−8
[1.232] [1.033] [1.469]
200/1782/4507 (0.1681) 106/910/2209 (0.174) 94/872/2298 (0.1624)
102/850/1879 (0.1862) 49/440/1011 (0.1793) 53/410/868 (0.1938)
98/932/2628 (0.1542) 57/470/1198 (0.1693) 41/462/1430 (0.1407)
rs2173201 (AA/AC/CC)
0.0005063 0.2231 0.0001093
[0.8584] [0.9274] [0.7823]
316/2286/3923 (0.2236) 172/1164/1924 (0.2313) 144/1122/1999 (0.2159)
127/933/1781 (0.2089) 81/512/917 (0.2232) 46/421/864 (0.1927)
189/1353/2142 (0.2349) 91/652/1007 (0.2383) 98/701/1135 (0.2319)
SNP: Single nucleotide polymorphism; BP: Base pair; OR: Odds ratio. MAF: Minor allele frequency.
Table 3. Genotype counts, allele frequencies, and Hardy–Weinberg Equilibrium (HWE) p-values for
rs1789891 in the combined sample, and the respective p-values in the subsamples. Genotype counts for
rs1789891 are shown; number of individuals with the respective rs1789891 genotype is shown.
Sample Subgroup Genotype CountsAA/AC/CC
Frequency of rs1789891 Risk Allele
for AD (A-allele); Frequency of
rs1789891 Protective Allele for AD
(C-Allele)
p HWE
Combined sample
(2831 cases, 3658 controls)
all 200/1782/4507 0.168; 0.832 0.14
affected 102/850/1879 0.186; 0.814 0.62
unaffected 98/932/2628 0.154; 0.846 0.16
ACP + ALC subsample
(1500 cases, 1725 controls)
all 106/910/2209 0.174; 0.826 0.30
affected 49/440/1011 0.179; 0.821 0.86
unaffected 57/470/1198 0.169; 0.831 0.20
ACP subsample (1101 cases) affected 35/320/746 0.177; 0.823 0.92
ALC subsample (399 cases) affected 14/120/265 0.185; 0.815 0.87
AD subsample (1331 cases,
1933 controls)
all 94/872/2298 0.162; 0.838 0.30
affected 53/410/868 0.194; 0.806 0.60
unaffected 41/462/1430 0.141; 0.859 0.57
In the pathway analysis of the combined sample, the top finding was the “Ethanol_Oxidation”
gene set, which contains ADH1B (puncorrected = 2.2 × 10−4; pcorrected = 0.15; Table 4).
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Table 4. Results of the genome-wide pathway analysis of the combined sample, and the respective
values in the subsamples. Pathways with puncorrected < 1 × 10−2 are shown. If a variant was located
within a region shared by more than one gene, the variant was assigned to all of the respective genes.
Pathway NGENES
BETA of
the
Combined
Sample
BETA_STD
of the
Combined
Sample
SE in the
Combined
Sample
p–Value in the
Combined
Sample (2841
Cases, 3684
Controls)
p-Value in the
ACP + ALC
Subsample (1510
Cases, 1750
Controls)
p-Value in the
AD Subsample
(1331 Cases,
1934 Controls)
Ethanol Oxidation 10 1.28 0.0312 0.364 0.00021694 0.061561 9.15 × 10−5
Organic Cation Anion
Zwitterion Transport 13 0.844 0.0234 0.267 0.00077746 0.025914 0.37297
Amino Acid
Transport across the
Plasma Membrane
28 0.429 0.0175 0.161 0.0037699 0.41315 0.52029
Basigin Interactions 23 0.428 0.0158 0.161 0.0038618 0.50705 0.17262
Recruitment of
NUMA to Mitotic
Centrosomes
9 0.746 0.0172 0.285 0.0044978 0.073773 0.27771
Trafficking and
Processing of
Endosomal TLR
9 0.739 0.0171 0.3 0.0068239 0.35393 0.313
BETA: Regression coefficient; STD: Standard deviation; SE: Standard error.
4. Discussion
To facilitate both the identification of new genes and pathways for AD and the replication of
previous results, the present study combined the cohorts of three previous investigations in order
to increase sample size to increase statistical power. The only association to withstand correction
for multiple testing was the association with ADH1B in the gene-based test. This association was
attributable to the AD subsample, and no association was detected in the ACP + ALC subsample.
On first inspection, the lack of association with ADH1B in the combined ACP + ALC sample may seem
surprising, since this gene is one of most consistently reported genes for AD and AC, and achieved
genome-wide significance in the present AD subsample. In the AD patient subsample, the frequency
of the A allele was higher (19.4% vs. 17.9%), and in the controls lower (14.1% vs. 16.9%) than in the
ACP + ALC subsample. The lack of association may be attributable to random or systematic genetic
differences within the patient and/or control samples.
4.1. Patients
1. For ACP and ALC, no explicit diagnosis of AD was required, and these patients may therefore
differ in terms of genetic disposition. However, the ACP and ALC patients were recruited
from a clinic specialized in the treatment of alcohol-induced somatic disorders. Furthermore,
in each patient, the respective disorder had been induced by excessive alcohol consumption,
and the majority of patients were unable to abstain from alcohol despite the assignment of the
somatic diagnosis.
2. The differing distribution of rs1789891 in the AD and ACP + ALC samples is non-random.
ADH1B metabolizes alcohol to acetaldehyde, and research suggests that the adverse effects of
acetaldehyde inhibit further drinking [31–33]. Alleles that confer an increased rate of alcohol
metabolism may also contribute to tissue damage [34]. This was illustrated in a recent study
from Japan, which analyzed rs1229984 (Arg48His) in ADH1B. The ADH1B 48His variant leads
to an increased level of acetaldehyde and is thus protective in terms of AD development. The
authors found that the ADH1B 48His variant was overrepresented in patients with alcoholic liver
cirrhosis and chronic alcoholic calcific pancreatitis [35]. ADH1B_48His has a low frequency in
Europeans [36–38], was not present in our genotyping arrays, and could not be imputed with
sufficient imputation quality (R2 = 0.44).
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In the present analyses, the ADH1B variant with the lowest p-value was rs1789891 (p = 1.315 × 10−5).
The rs1789891 variant is located between the genes ADH1B and ADH1C. Although both genes are
expressed in the liver [39] and pancreas [40], rs1789891 has no known function according to the
NCBI Phenotype-Genotype Integrator [41]. However, rs1789891 is in high LD with the functional
variants rs1693482 (Arg272Gln) and rs698 (Ile350Val) in the gene ADH1C (Figure S2). These two
ADH1C missense variants Arg272Gln and Ile350Val typically occur together (r2 = 1.0), and result in
two different forms of ADH1C: (i) the ADH1C isoenzyme gamma1 (ADH1C*1), in which arginine
is present at amino acid position 272 and isoleucine at amino acid position 350; and (ii) the ADH1C
isoenzyme gamma2 (ADH1C*2), in which glutamine is present at amino acid position 272 and valine
at amino acid position 350. Although ADH1C_Arg272/Ile350 (which correspond to the rs1789891
C-allele) confers a rapid rate of ethanol oxidation [42,43], its effect on the rate of alcohol metabolism
is weaker than that of ADH1B_48His. However, imputation of rs1693482 and rs698 showed that the
associations with rs1693482 (p = 1.43 × 10−5) and rs698 (p = 1.798 × 10−5) were weaker than with
rs1789891 (p = 1.315 × 10−5). Thus, the issue of whether the association with rs1789891 is mainly
attributable to LD with rs1693482 and rs698, or whether further variants in this region are implicated,
remains unclear. Variants rs1693482/rs698 could nevertheless be the contributory factor in terms of
organ damage [44–46], since they are in LD with rs1789891.
Two plausible hypotheses can be formulated to explain how the products of the ADH reaction
may increase the risk of tissue damage in the pancreas and liver. First, acetaldehyde accumulation in
response to chronic alcohol ingestion has been implicated in the etiology of liver cirrhosis, pancreatitis,
brain damage, cardiomyopathy, fetal alcohol syndrome, and various forms of cancer [34]. Whereas
the allele or genotype differences in some studies were non-significant, several investigations have
reported a lower frequency of alcoholism-susceptibility alleles or genotypes in patients with alcoholic
liver disease or alcoholic pancreatitis (reviewed in [35]). The cytotoxic acetaldehyde that is formed
as an intermediate in the metabolism of ethanol is reported to induce morphological changes in the
pancreas of experimental animals [47]. In addition, acetaldehyde has reported fibrogenic effects in the
liver [48]. The likely molecular mechanism through which acetaldehyde causes organ damage is the
promotion of adduct formation, which leads to protein and DNA damage [48].
Second, nicotinamide adenine dinucleotide (NAD+) is an intermediate electron carrier in the
cytosolic ADH-mediated metabolism of alcohol to acetaldehyde. In this reaction, NAD+ is reduced
to NADH by two electrons. In a subsequent step, the electrons of NADH are transferred to O2 in
the mitochondrial respiratory chain, which captures H+ to yield H2O. Ethanol metabolism therefore
increases the O2 requirement of hepatocytes, and may result in hepatocyte hypoxia [49]. This may lead
in turn to organ damage.
4.2. Controls
Random fluctuation seems very likely when looking at allele frequencies in the control samples.
A detailed inspection of rs1789891 allele frequencies in the present control subsamples (data not shown)
was therefore performed. Despite the fact that the control sample used for the ALC + ACP samples
was drawn from the same study as a subcohort of the AD controls, it displayed a higher frequency of
the AD risk allele A (16.9%) than the corresponding control subcohort used for AD (13.9%).
5. Conclusions
The aim of the present study was to identify new genes and pathways for AD, and to confirm
previously reported findings, by combining three previously investigated samples. No novel data
were generated. The fact that the previously reported association with ADH1B was not observed in
the ACP + ALC subsample may reflect genetic stratification in cases and/or random fluctuation in
allele frequencies in controls. This finding demonstrates that even strong signals can be blurred, if
samples are small and heterogeneous with possible opposing effects. Our finding therefore stresses
the necessity for, and central importance of samples that are large and well characterized, such as
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those investigated within the context of the Psychiatric Genomics Consortium. The present authors
are optimistic that as has been the case with other psychiatric disorders, the possibilities offered by
GWAS will ultimately generate major contributions to our understanding of the genetic background of
the alcohol use disorders.
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